WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinic's Center for ... SHANGHAI, Nov. 4, 2013 /PRNewswire/ -- WuXi PharmaTech (WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced a licensing agreement with Mayo Clinic's Center for Individualized Medicine to expand WuXi's collection of patient-derived xenograft (PDX) mouse models. These models ...
Nov. 4, 2013 - PR Newswire via Yahoo! Finance
WuXi PharmaTech inks licensing agreement with Mayo Clinic for PDX models WuXi PharmaTech ( WX +0.6% ) announces a licensing agreement with Mayo Clinic's Center for Individualized Medicine. The deal gives WX an exclusive license to a "panel of patient-derived xenograft [mouse] models for prevailing cancers in Western countries." Ultimately, the goal here is to give WX a more extensive portfolio of models so that the company's customers can "select highly relevant ...
Nov. 4, 2013 - Seeking Alpha